Manual
Description
Fatty acid-binding proteins (FABPs) are a class of cytoplasmic proteins that bind long chain fatty acids. FABPs are small intracellular proteins (~13-14 kDa) with a high degree of tissue specificity. They are abundantly present in various cell types and play an important role in the intracellular utilization of fatty acids, transport and metabolism. There are at least nine distinct types of FABP, each showing a specific pattern of tissue expression. Due to its small size, FABP leaks rapidly out of ischemically damaged necrotic cells leading to a rise in serum levels. Ischemically damaged tissues are characterized histologically by absence (or low presence) of FABP facilitating recognition of such areas.
The H-FABP protein is derived from the FABP3 gene. The FABP content of rat heart muscle (H-FABP) is markedly high, 10-20 mol% of cytoplasmic proteins. Following acute myocardial infarction (AMI) the small protein H-FABP is rapidly released in to the circulation. Significantly elevated serum/plasma concentrations are found within 3 h after AMI which generally return to normal values within 12 to 24 h. These features make H-FABP a useful research tool for the early assessment or exclusion of AMI, and for the monitoring of a recurrent infarction. Constitutive H-FABP released from the heart after AMI is quantitatively recovered in serum/plasma. Thus assessment of H-FABP is also a very effective tool for the estimation of the infarct size. The Rat H-FABP kit can also be used for measurement of brain-type FABP, a marker for brain injury detection.
In serum/plasma of healthy individuals approximately 1.6 ng/ml of H-FABP is present.
Cross Reactivity
|
Potential cross reacting proteins detected in the rat H-FABP ELISA.
|
|
Cross reactant
|
Reactivity
|
|
Swine H-FABP
Human H-FABP
Rat I-FABP
Rat L-FABP
|
Strong
Negative
Negative
Negative
|
Application
The rat H-FABP ELISA has been developed for the quantitative measurement of natural rat heart FABP in serum and plasma. The ELISA can be used to detect heart damage. In serum or plasma samples, rat H-FABP can be measured accurately if serum or plasma samples are diluted at least 2 times.
Features
- Minimum concentration which can be measured is 400 pg/ml rat H-FABP.
- Measurable concentration range of 390-25,000 pg/ml.
- The kit contains one standard
- Working volume of 100 µl/well.
Typical standard curve
Principle
- The rat H-FABP ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 2½ hours for Rat H-FABP.
- The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay.
- Samples and standards are captured by a solid bound specific antibody.
- Biotinylated tracer antibody will bind to captured rat H-FABP.
- Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody.
- Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB).
- The enzyme reaction is stopped by the addition of citric acid.
- The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the mouse/rat H-FABP standards (log).
- The H-FABP concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
Aliases
FABP3, Muscle fatty acid-binding protein, Mammary-derived growth inhibitor
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least six months. After reconstitution the reagents are stable for 1 month if stored at 2-8°C.
References
- Aartsen, W et al; Heart fatty acid binding protein and cardiac troponin T plasma concentrations as markers for myocardial infarction after coronary artery ligation in mice. Eur J Physiol 2000, 439: 416
- Van der Lee, K et al; Fasting-induced changes in the expression of genes controlling substrate metabolism in the rat heart. J Lipid Res 2001, 42: 1752
- Wunderlich, M et al; Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol, 2005, 252: 718
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Also available
Scientific info
Heart FABP, FABP3, a biomarker of skeletal muscle toxicity
H-FABP as a serological biomarker of SKM (skeletal muscle) injury in rats has proven to be more sensitive, to have higher concordance, more positive predictive value, more negative predicted value and specificity than the established markers of SKM injury1.
The established markers of SKM injury, creatine kinase-MM isoenzyme (CK) and aspartate aminotransferase (AST), have been useful for identifying SKM toxicity, but lack the sensitivity necessary to identify more subtle drug-related effects on SKM.
FABP3 is as reported before also a sensitive and rapid biomarker for myocardial injury2. The sensitivity of FABP3 is attributed to its high concentration in heart tissue. The rapidity of its response is attributed to the small size of the protein (14kDa), which facilitates its release from the cytoplasm of damaged tissue.
The rat/mouse H-FABP ELISA (Cat.# HK403) is a reliable assay to measure H-FABP protein concentrations in serum and supernatants of tissue homogenates. This is based on spiking results and high concordance with a mass-spectrometry-based analytical method for serum1.
See Furuhashi et al.3 for More information about FABPs
References:
- Pritt, M et al; Fabp3 as a biomarker of skeletal muscle toxicity in the rat: comparison with conventional biomarkers. Toxicol Sci 2008, 103: 382
- Pelsers, M et al; Fatty acid binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005, 352: 15
- Furuhashi, M et al; Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008, 7: 489